Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04752475 · ClinicalTrials.gov registry record · Phase 3

Lasix for the Prevention of De Novo Postpartum Hypertension

A Phase 3 study, sponsored by Columbia University.

Completed
Registry status
Phase 3
Development phase
82
Enrollment target

NCT04752475 is a Phase 3 study that has completed, run by Columbia University. The registered enrollment target is 82 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04752475, a Phase 3 study, has completed, sponsored by Columbia University.

COMPLETED
Registry status
Phase 3
Development phase
82 participants
Enrollment target

Study Summary

Primary objective: To evaluate whether oral furosemide can help prevent de novo postpartum hypertension (new-onset high blood pressure after delivery) by reducing blood pressure after delivery in high-risk women. Secondary objectives: To evaluate whether oral furosemide administered to high-risk women after delivery can reduce the frequency of postpartum hypertensive episodes, the need for antihypertensive therapy, the risk of postpartum preeclampsia, and the incidence of severe maternal morbidity.

Interventions

  • OTHER Placebo
  • DRUG Furosemide

Trial Details

FieldValue
Enrollment Target 82 participants
Start Date 2021-10-20
Est. Completion 2022-05-28
Phase Phase 3

Sponsor

Columbia University

958 total trials

What the Registry Record Tells You About NCT04752475

The ClinicalTrials.gov registry entry for NCT04752475 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT04752475 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04752475 about?

NCT04752475 is a clinical study titled "Lasix for the Prevention of De Novo Postpartum Hypertension". Primary objective: To evaluate whether oral furosemide can help prevent de novo postpartum hypertension (new-onset high blood pressure after delivery) by reducing blood pressure after delivery in high-risk women. Secondary objectives: To evaluate whether oral furosemide administered to high-risk wo...

What is the current status of trial NCT04752475?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 82 participants. The study started on 2021-10-20. Estimated completion is 2022-05-28.

What interventions are being tested in trial NCT04752475?

The interventions under investigation include: Placebo (OTHER), Furosemide (DRUG).

Who is sponsoring clinical trial NCT04752475?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.